Aeglea Biotherapeutics effects 1-for-25 reverse stock split and reduces authorized shares to 20M

Spyre Therapeutics, Inc.

Reverse stock split at 1-for-25 ratio effective Sept 8, 2023; no fractional shares issued; cash in lieu.
Authorized common shares reduced from 500M to 20M.
Proportional adjustments to Series A preferred conversion, outstanding warrants, and equity awards.
Corporate presentation: adjusted total capitalization ~47.7M shares as-converted as of June 22, 2023.
2022 net loss per share restated to $(24.86) on weighted-average shares of 3.37M post-split.

item 3.03 item 5.03 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Spyre Therapeutics, Inc.: Filed Certificate of Amendment to Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split and reduction of authorized shares from 500,000,000 to 20,000,000 (effective 2023-09-08).

Change: charter amendment
Effective: 2023-09-08

Exact text from the filing

To effect the Reverse Stock Split and the Authorized Shares Reduction, on September 7, 2023, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Amendment”).

View on SEC.gov

Browse all governance changes →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-231646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.